Exact Sciences (EXAS) Stock: Abbott’s $23 Billion Deal, Q3 Earnings Beat and What Investors Should Watch Now
Abbott Laboratories has agreed to acquire Exact Sciences for $105 per share in cash, valuing the deal at up to $23 billion including debt. Exact Sciences stock traded at $101.27 mid-day December 1, near its all-time high after a 56% surge in November. The transaction is expected to close in Q2 2026, pending approvals. The offer represents a 22% premium to Exact’s pre-deal price.